EDITORIAL IRA

Dear All

Vacation time. For innocence for sure, also for some of us. There is a need to try and mesmerize you more with the contents of this issue, so you do not forget it amongst your mountainous or aquatic adventures during the holidays.

We welcome the new IRA Puducherry Chapter, which was formed recently. There are important announcements in the Secretary’s Message and reports of at least 4 CMEs done in the last quarter of this year. We again request IRA members/office bearers to report important CMEs done in their areas to us, so that we may include them in our issue, especially those remote areas, where little is being done for the cause of rheumatology.

Science does not take a holiday, and in this issue, out of many significant studies, on the clinical front, the EMBARK study, wherein etanercept not only halted radiologic progression but actually did a ‘refill,’ is a landmark one, especially now that more and more biosimilars are accessible to those who can afford them in our country. Amongst the more basic studies, a new possible NIK (NF kappa B inducing kinase) inhibitor may be a useful drug for lupus, as it has been shown in animal models how it effectively inhibits both BAFF and T-cell parameters in the spleen and inflammation in kidneys.

Read more

From the IRA

A new state chapter of IRA in Puducherry, entitled ‘Puducherry Chapter of IRA,’ was formed in the presence of our esteemed President IRA Dr. Debashish Danda, Lt. Gen. Ved Chaturvedi, and other members.

Dr. RP Swaminathan (Dean, Academic JIPMER) was installed as President of the Chapter; Dr. VS Negi is Vice-President and Dr. Chanaveerappa B, the Treasurer.

A rheumatology CME was also held at JIPMER, during the formation of the IRA Puducherry Chapter.

1. IRA international travel fellowships: IRA will award 5 travel fellowships (2 for APLAR [Rs. 30,000 each], 2 for ACR [Rs. 50,000 each], and 1 for other meeting [maximum of Rs. 50,000] members less than 40 years of age who have an accepted paper to attend international rheumatology meetings). The priority would be in the order of oral paper, poster, quiz, etc. The last date of application is 15 June for APLAR and 15 August for ACR meeting. For the remaining meetings, applications can be sent after abstract acceptance. All applications should be sent to the Secretary, IRA.

2. CME: IRA is also going to conduct 6 CMEs in medical colleges in different parts of India where there have been no CMEs in the past. In addition to these, there will also be a single-theme IRA mid-term CME. Interested members can mail the Secretary, IRA.

Read more

QUARTERLY HIGHLIGHTS

Dr C Balakrishnan, Consultant Rheumatologist, Hinduja hospital, Mumbai

Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis. 2018 Feb;77(2):203-211. doi: 10.1136/annrheumdis-2017-211782. Epub 2017 Oct 25.

Introduction: The second-generation anti-cyclic citrullinated peptide (anti-CCP2) assay detects the majority but not all anticitrullinated protein/peptide antibodies (ACPA). Anti-CCP2-positive rheumatoid arthritis (RA) is associated with HLA-DRB1*-shared epitope (SE) alleles and smoking. Using a multiplex assay to detect multiple specific ACPA, we have investigated the fine specificity of individual ACPA responses and the biological impact of additional ACPA reactivity among anti-CCP2-negative patients.

Methods: We investigated 2825 patients with RA and 551 healthy controls with full data on anti-CCP2, HLA-DRB1* alleles, and smoking history concerning reactivity against 16 citrullinated peptides and arginine control peptides with a multiplex array.

Read more

Patient's Perspective

Patients’ perspectives on dietary influence of arthritis

A survey on the influence of diet on arthritis symptoms in patients with rheumatoid arthritis was done in a rheumatology clinic.The questionnaire was administered, and responses was recorded by a physiotherapist.

A total of 75 adult patients who were taking South Indian food were interviewed, among whom 47 patients had a worsening of symptoms due to a vegetarian diet.Twenty-eight patients (37 %) had a worsening of pain in the joints when they ate a nonvegetarian diet. None of them had any improvement in their symptoms with any type of food.

For vegetarian diets, potato tops the list, with 30 percent of the patients reporting worsening of joint pain and 22 percent reporting worsening due to the consumption of bitter gourd.Other vegetables that were reported to worsen symptoms were mushroom, cabbage, okra, and cauliflower.Dal was reported to worsen symptoms in 5 patients.

For nonvegetarian diets, fried chicken worsened symptoms in 50 percent and meat in 22 percent of the patients.Egg and fish contributed for the rest of the symptoms. Some of them reported worsening of pain with fried food. Other food items that were said to be reasons for exacerbation of symptoms included milk, yogurt, and cereals.

FELLOWS’ CORNER

Dr Shefali Sharma, Rheumatology, PGIMER, Chandigarh

Gastrointestinal Amyloidosis Manifesting as Chronic Diarrhea in a Case of Rheumatoid Arthritis

Prasanth Balasubramanian, Department of Internal Medicine, PGIMER, Chandigarh

A 58-year-old lady with a history suggestive of inflammatory joint pains since 17 years of age and very poor compliance to treatment presented with chronic diarrhea for 2 months. On examination, the patient had a Z-shaped thumb deformity and flexion deformity of her fingers, which are typically seen in rheumatoid arthritis.

On evaluation, the patients’ complete blood counts were: Hemoglobin (Hb): 7.3 g/dL, total leukocyte count (TLC): 11.2× 109/L with differential leukocyte count: polymorphs 70%, lymphocytes 22%, eosinophils 4%, and basophil 4%, platelet count 236 × 103; ESR was 55 mm/h, and peripheral smear showed microcytic-to-normocytic RBCs and hyperchromasia. Biochemistry investigations revealed serum sodium 135mmol/L, serum potassium 3.5mmol/dL, blood urea nitrogen48 mg/dL, creatinine 2.1 mg/dL, total protein 4.8 mg/dL, serum albumin 1.6 with albumin:globulin ratio of 1:3.8, serum calcium 8.8 mg/dL.

MY LIFE, MY TIMES

Interviewer: Dr Banwari Sharma, Interviewee: Dr. Debashish Danda, President, IRA and HoD, Dept of Rheumatology, CMC Vellore

Que 1: What’s your number-one plan for IRA?

My number-one plan for IRA is to establish the IRA college and the two-year post-doctoral fellowship program, a long overdue dream of IRA, to overcome the acute shortage of trained rheumatologists in our country. The 2-year training program will have minimum standard guidelines, and it will be like a compressed DM program without diluting the quality. Although it is not an MCI or a university program, this will improve the standards of many fellowship programs already running across the country.

Interested centers will be inspected by the IRA college, and the IRA education cell will oversee infrastructure, faculty, syllabus, and the guidelines for selection of candidates, as well as the continuous evaluation process and final exit exam. There are several societies, such as Critical Care and Pediatric Immunology, that run such training programs.

Read more

Industry Desk

Immune checkpoint inhibitors: What we must know…

Ramya Janardana, Assistant Professor, Department of Clinical Immunology and Rheumatology, St John’s Medical College Hospital, Bangalore-34

Immune checkpoint inhibitors [ICI] have brought about a paradigm shift in the management of a few solid cancers such as melanoma, non-small cell lung cancer, prostate, urothelial tumors, etc. The indications of their use are expanding each day.

ICIs are molecules designed to block co-inhibitory proteins such as cytotoxic T lymphocyte antigen-4 (CTLA-4), or programmed cell death-1 (PD-1) or its ligands (PD-L-1)—found on T cells or cancer cells. Blocking inhibitory checkpoints amplifies immune system activity against certain tumors. Ipilimumab (anti CTLA-4), Pembrolizumab (anti PD-1), Nivolimumab (anti PD-1), Atezolizumab (anti PD-L1), Avelumab (anti PD-L1), and Durvalumab (anti PD-L1) are FDA-approved for use in various malignancies.

CLINICAL PEARLS

Urate lowering in gout: Allopurinol vs. Febuxostat

Gout is due to supersaturation (crystal formation) of urate in body fluids. Gout flares can be eliminated by maintaining low serum urate levels (<5 g/dL in tophaceous “severe” gout, and <6 g/dL in all other forms of gout).1 Gout is often a part of metabolic syndrome and is associated with increased cardiovascular mortality.2

Urate-lowering therapy is advised for recurrent gout attacks (>1 flare annually), radiological joint damage due to gout, gouty tophi, and renal disease (creatinine clearance <60 mL/minute/1.73 m2) or urolithiasis. Colchicine and NSAIDs prevent gout flares, but cannot prevent silent erosions and tophi deposition. Allopurinol has been the gold standard since its introduction 7 decades ago3.

Other drugs include uricosurics such as probenecid and benzbromarone; xanthine oxidase inhibitor febuxostat; uricase pegloticase and rasburicase. The latest uricosuric is lesinurad, which inhibits URAT1 (urate reabsorption in renal tubules).